Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Looks like Molnupiravir isn't such a good choice for treating Covid. Slow clearance and induction of mutations doesn't seem like something you would want in an anti-Covid drug. It sure seems to me that EDP-235 is a good option to treat Covid. Now if ENTA can just convince another company to think so and partner we will be in business.

The researchers found that molunpiravir initially lowered patients’ viral load more quickly than usual care, with 14% of molnupiravir patients having cleared the virus by day five, compared to only 2% of the usual care group.

However, post-treatment the rate of viral decline in molnupiravir-treated participants significantly slowed. Nine days after treatments, only 48% of molnupiravir-treated patients had cleared the virus, compared to 56% of the patients receiving usual care.

Furthermore, virus from these later samples contained more mutations than those seen in the usual care group. The researchers were able to grow some of these mutated viruses in the lab from samples taken up to nine days post-treatment, which suggests they could potentially be passed from patients who have taken molnupiravir to others.

https://www.ucl.ac.uk/news/2024/feb/covid-19-antiviral-treatment-should-be-taken-longer

Many thanks to Preciouslife1 for the heads up to that link.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173930925